The upcoming The FLORetina International Congress on OCT Angiography, En Face OCT, and Advances in OCT (FLORetina-ICOOR) in Florence, Italy, is hosting 57 exhibitors who will showcase their latest ...
Panelists discuss how differing disease mechanisms, inflammatory drivers, and clinical priorities across AMD, DME, and RVO shape individualized therapeutic goals and the use of newer anti-VEGF agents.
Catch up on this week's highlights in retina. Keep your retina practice on the forefront—subscribe for expert analysis and emerging trends in retinal disease management.
The EURETINA meeting featured new treatments in gene therapy and innovative implants to enhance patient quality of life. Frank Holz, MD, FEBO, FARVO, a retina specialist from Bonn, Germany, discusses ...
ISTH0036 demonstrates potential to prevent fibrosis, reduce retinal fluid, and improve vision in AMD and diabetic macular edema patients. Marion Munk, MD, PhD, talked with Modern Retina® during the ...
Beacon Therapeutics shares promising phase 2 trial results for laru-zova, a gene therapy showing potential in treating X-linked retinitis pigmentosa. Beacon Therapeutics recently revealed topline data ...
David A. Eichenbaum, MD, FASRS, a partner and director of research at Retina Vitreous Associates of Florida and collaborative volunteer Associate Professor at the Morsani College of Medicine at the ...
Neurotech Pharmaceuticals performs the first ENCELTO procedure. Neurotech Pharmaceuticals recently announced the first commercial manufacturing, shipment, and surgical procedure of the first and only ...
Dilsher S. Dhoot, MD, FASRS, shares insights on avoralstat, a promising treatment for diabetic macular edema, at ASRS 2025. The American Society of Retina Specialists (ASRS) is holding their 2025 ...
Opus Genetics partners with the Global RDH12 Alliance to advance gene therapy for inherited retinal disease, aiming for FDA application by late 2025. To strengthen Opus Genetics’ gene therapy program ...
The completion of the full BLA submission is anticipated in early 2026 and is eligible for priority review under the program’s fast-track designation. Today Nanoscope Therapeutics announced its ...
Nanoscope Therapeutics establishes a Vision Advisory Committee to enhance retinal care and drive innovative therapies for vision restoration. Biotechnology company Nanoscope Therapeutics recently ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback